Biomarker ID | 1909 |
PMID | 30401717 |
Year | 2019 |
Biomarker | ALDH1A3; APH1B; ATAD1; CTBS; CTSO; DHRS7; ESR1; FOXC1; MEIS2; NR4A1; PDE8B; RPS27L; SEC62; SPCS3; ZMAT1; |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in Metastatic PCa |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Primary Prostate Cancer Vs Metastatic Prostate Cancer |
Type of Biomarker | Prognostic |
Cohort | 491 patients with primary Prostate cancer and 1 with metastatic prostate cancer was used from the TCGA cohort. Results were validated on GEO cohort: GSE21034. Results shown here are for GEO cohort |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | RNA-Seq |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |